Staphylococcal and streptococcal toxic shock syndrome

01OverviewDefinition, clinical context and the essential points that orientate the chapter.

Staphylococcus aureus and group A Streptococcus can produce exotoxins that act as superantigens, activating a large fraction of T cells without normal antigen specificity. The resulting cytokine surge causes vasoplegia, capillary leak and organ injury.

Staphylococcal toxin may arise from a relatively small mucosal or wound focus and is often not accompanied by bacteraemia. Streptococcal toxic shock usually reflects invasive tissue infection with bloodstream spread.

Diagnosis is clinical and must precede confirmatory microbiology. Rash, mucosal change and later desquamation support staphylococcal disease, while disproportionate focal pain and necrosis strongly support invasive streptococcal disease.

Survival depends on early haemodynamic and respiratory support, immediate removal of infected or retained material, radical debridement when needed and active therapy that both kills organisms and limits further toxin synthesis.

Key points

Toxic shock syndrome is a superantigen-driven clinical syndrome of fever, hypotension, rash or soft-tissue focus and multiorgan dysfunction.
Staphylococcal disease often has diffuse sunburn-like erythroderma, mucosal hyperaemia, vomiting and later palm and sole desquamation; blood cultures may be negative.
Streptococcal toxic shock commonly accompanies bacteraemia, severe focal pain, necrotising fasciitis or myositis and has high mortality.
Do not wait for desquamation or full surveillance criteria before treating a clinically compatible shock syndrome.
Remove the toxin source immediately: tampon, packing and infected device, or operative drainage and debridement of wound, uterus or deep soft tissue.
Start broad bactericidal intravenous cover plus clindamycin toxin suppression after cultures without delaying sepsis treatment.
Confirmed susceptible group A streptococcal disease is treated with benzylpenicillin 2.4 g every four hours plus clindamycin 1.2 g every six hours intravenously.
Intravenous immunoglobulin is not routine; discuss selected refractory severe streptococcal toxic shock with critical care, infection specialists and transfusion services.

02AetiologyUnderlying causes, associations and risk factors, with why each one matters.

Staphylococcal superantigen strains

Toxin-producing Staphylococcus aureus colonises or infects mucosa, packing, burns or wounds and can cause systemic illness without bacteraemia.

Invasive group A Streptococcus

Streptococcus pyogenes enters injured skin, fascia, muscle, postpartum tissue or bloodstream and often causes bacteraemic toxic shock.

Foreign-body and wound sources

Tampons, nasal packing, postoperative foreign material and devitalised tissue provide protected high-burden niches for continued bacterial superantigen toxin production.

03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.

1
Superantigen T-cell activation
Exotoxins bridge antigen-presenting cells and T-cell receptors outside the normal binding site, activating a large nonspecific lymphocyte population.
2
Cytokine and endothelial injury
Massive cytokine release produces vasodilatation, capillary leak, myocardial depression and microvascular dysfunction leading to tissue hypoperfusion.
3
Multiorgan dysfunction
Systemic hypoperfusion and direct inflammatory injury affect kidneys, liver, lungs, brain, skeletal muscle, platelets and multiple coagulation pathways simultaneously.
4
Source-dependent persistence
Toxin release continues while infected packing, abscess, uterus or necrotic fascia remains, despite transient haemodynamic improvement with antibiotics.

04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.

Shock with diffuse erythrodermaRed flag

Fever, hypotension, generalised sunburn-like erythema and conjunctival, oral or vaginal hyperaemia suggests staphylococcal toxic shock.

Gastrointestinal prodromeRed flag

Abrupt vomiting, diarrhoea, severe myalgia and headache can precede shock and rash, particularly in staphylococcal disease.

Streptococcal focal painRed flag

Intense limb, wound, pelvic or soft-tissue pain with swelling and early shock may indicate invasive group A streptococcal infection.

Multiorgan patternRed flag

Acute kidney injury, thrombocytopenia, coagulopathy, hepatic injury, encephalopathy, respiratory failure and creatine-kinase elevation reflect systemic toxin injury.

Delayed desquamation

Peeling of palms and soles one to two weeks later supports staphylococcal toxic shock but is too late to guide initial treatment.

Hidden sourceRed flag

Menstrual products, nasal packing, postoperative wounds, burns, postpartum genital tract and deep soft tissues require deliberate inspection.

Red flags requiring action

Hypotension, rising lactate, confusion, oliguria or hypoxaemia indicates established shock and organ failure.
Severe focal limb or wound pain can be the only early clue to invasive group A streptococcal necrosis.
Diffuse erythema with conjunctival or mucosal hyperaemia and shock suggests staphylococcal toxic shock.
Haemorrhagic bullae, skin anaesthesia, crepitus or rapidly spreading oedema requires immediate surgical exploration.
Tampon, nasal packing, wound packing, device or retained foreign material can maintain toxin production.
Postpartum, postoperative and varicella-associated disease require deliberate examination of concealed wounds and genital or uterine sources.

05InvestigationsWhat to request, why it matters and how to interpret it.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
Blood culturesFirst step
Why
Identify invasive streptococcal or staphylococcal bacteraemia before antibiotics.
Interpretation and limitations
Streptococcal toxic shock commonly yields positive cultures; negative blood cultures do not exclude a toxin-producing staphylococcal focus.
02
Source cultures and deep tissue
Why
Recover the organism from wound, vagina, packing, abscess or operative tissue for susceptibility and toxin-source definition.
Interpretation and limitations
Take deep tissue during debridement and do not allow a low-yield superficial swab to delay source removal.
03
Blood gas, lactate and glucose
Why
Assess tissue hypoperfusion and metabolic disturbance during immediate resuscitation.
Interpretation and limitations
Trend lactate with capillary refill, blood pressure, urine output and vasopressor need; normalisation does not prove source control.
04
Full blood count and coagulation
Why
Detect thrombocytopenia, haemoconcentration, disseminated coagulation and bleeding risk.
Interpretation and limitations
Falling platelets and prolonged clotting indicate severity but also occur in other septic and inflammatory shock syndromes.
05
Renal, liver and creatine kinase profile
Why
Document multiorgan injury, rhabdomyolysis and safe antimicrobial dosing.
Interpretation and limitations
Rising creatinine, transaminases and CK support the syndrome and guide organ support; no single abnormality is diagnostic.
06
Imaging of suspected source
Why
Map abscess, retained material, uterine infection or deep fascial and muscle involvement when imaging will guide intervention.
Interpretation and limitations
CT, ultrasound or MRI may assist a stable uncertain case but must not delay removal or exploration of a clinically apparent source.
07
ECG and cardiac assessment
Why
Assess shock-related myocardial dysfunction, arrhythmia and interacting medicine risk.
Interpretation and limitations
Toxic and septic myocardial depression can require echocardiography and critical-care support; interpret troponin with the full shock context.

06Differential diagnosisRealistic alternatives and the features that help distinguish them.

Non-toxin septic shock

Other bacterial infections cause vasoplegia and organ failure without the characteristic rash, mucosal findings or focal necrotising pain.

Meningococcal disease

Fever, shock and rash may reflect invasive meningococcaemia, particularly when non-blanching purpura, headache or other meningeal features coexist.

Anaphylaxis

Abrupt hypotension, urticaria, angioedema and bronchospasm after a relevant exposure suggests mast-cell-mediated anaphylactic shock requiring immediate intramuscular adrenaline.

Severe drug eruption

Stevens–Johnson syndrome, toxic epidermal necrolysis and DRESS cause rash and systemic illness with medication timing and mucosal or eosinophilic clues.

Kawasaki-like inflammation

Mucosal change, rash and shock from inflammatory syndromes can resemble toxic shock, requiring age, exposure and microbiology context.

07ManagementImmediate care, first-line treatment, alternatives and escalation.

01FIRST HOURResuscitate and suppress toxinFirst stepFever, hypotension and compatible rash, focal pain or multiorgan dysfunction makes toxic shock plausible.

1Use ABCDE, provide oxygen when indicated, establish access, measure lactate and glucose, take blood cultures and begin physiology-guided crystalloid resuscitation.
2Start the local severe sepsis and toxic-shock intravenous regimen immediately, including high-dose clindamycin when streptococcal or staphylococcal toxin disease is suspected.
3Begin vasopressor and critical-care support promptly when hypotension persists and monitor urine output, perfusion, acid-base status and respiratory failure.
4Notify surgery, obstetrics, gynaecology, ENT or another source team immediately according to the likely concealed or deep focus.

02SOURCERemove toxin-producing materialA tampon, pack, device, abscess, wound, uterus or necrotic soft-tissue source is identified or strongly suspected.

1Remove tampons, nasal or wound packing and removable contaminated material immediately and inspect the cavity and surrounding tissue.
2Drain abscess and perform wide surgical exploration and debridement for necrotising soft-tissue infection without waiting for imaging or laboratory scores.
3Send blood and multiple deep source samples for culture before antibiotics when this does not delay treatment or source control.
4Plan repeat examination and operative re-exploration because continuing shock can reflect retained necrotic tissue despite an apparently adequate first procedure.

03DIRECTNarrow bactericidal therapyCultures and source findings distinguish group A streptococcal, methicillin-susceptible staphylococcal or resistant infection.

1For susceptible group A Streptococcus, use benzylpenicillin plus clindamycin and continue surgical source control and critical-care support.
2For methicillin-susceptible Staphylococcus aureus, use high-dose flucloxacillin plus an initially toxin-suppressing agent under microbiology guidance.
3For MRSA or severe beta-lactam allergy, select active bactericidal and toxin-suppressing therapy with microbiology, using weight and serum-level protocols where required.
4Reassess the need for clindamycin as toxin production and bacterial burden fall and document route, duration and adverse-effect monitoring.

04REFRACTORYEscalate persistent shockEscalationShock and organ failure continue despite fluids, vasopressors, active antibiotics and credible source control.

1Repeat source examination and imaging or return to theatre to exclude retained pack, collection, devitalised tissue or another septic focus.
2Optimise ventilation, vasopressors, renal support, coagulation, glucose, electrolytes and nutrition with critical care.
3Discuss intravenous immunoglobulin for selected severe streptococcal toxic shock with infection, critical care and transfusion specialists, recognising uncertain evidence.
4Continue daily culture, antimicrobial and device review and remove every unnecessary intravascular or foreign-body source.

Key medicines and prescribing safety4 treatments · regimens, roles and cautions

Combines rapid bactericidal treatment with inhibition of continued streptococcal exotoxin and protein synthesis.

Benzylpenicillin plus clindamycin for GAS

Give benzylpenicillin 2.4 g intravenously every four hours plus clindamycin 1.2 g intravenously every six hours for confirmed susceptible group A streptococcal toxic shock.

Check immediate penicillin allergy, renal and hepatic function and clindamycin-associated diarrhoea; treatment complements but never replaces debridement of invasive soft-tissue disease.

Provides high-dose staphylococcal killing and early toxin suppression after source culture defines methicillin susceptibility.

Flucloxacillin plus clindamycin for MSSA

Give flucloxacillin 2 g intravenously every four to six hours plus clindamycin 1.2 g intravenously every six hours when directed for susceptible staphylococcal toxic shock.

Clarify penicillin allergy, monitor hepatic and renal function and sodium load, review clindamycin duration and remove every toxin-producing pack, device or collection.

Covers staphylococci, streptococci and source-specific polymicrobial organisms before cultures permit directed therapy.

Empirical toxic-shock regimen

Give the exact local broad intravenous severe soft-tissue or toxic-shock combination immediately, adjusted for source, allergy, renal function, MRSA risk and recent microbiology.

Use microbiology and critical-care input, apply weight and level monitoring for glycopeptides or aminoglycosides and narrow promptly after deep cultures and source control.

May neutralise circulating superantigens in selected life-threatening disease where shock persists despite standard care.

Intravenous immunoglobulin

Use only the specialist-approved weight-based intravenous immunoglobulin regimen for selected refractory severe streptococcal toxic shock after source control and active antibiotics.

Evidence is uncertain and supply is constrained; discuss with critical care, infection and transfusion specialists and assess thrombosis, haemolysis, renal injury and infusion-reaction risk.

08ComplicationsImportant consequences, why they occur and why they matter clinically.

Refractory shock

Profound vasoplegia, capillary leak and myocardial depression can require high-dose vasopressors, invasive ventilation and specialist mechanical circulatory-support assessment.

Renal and hepatic failure

Severe hypoperfusion, rhabdomyolysis and systemic inflammation cause acute kidney injury and hepatocellular dysfunction that may require prolonged organ support.

Disseminated coagulation

Platelet consumption and pathological coagulation activation produce disseminated microvascular thrombosis, purpura, clinically important bleeding and peripheral tissue ischaemia.

Limb loss

Necrotising streptococcal soft-tissue infection may require repeated extensive excision or limb amputation to control all toxin-producing devitalised tissue.

Recurrence

Persistent colonisation or re-exposure to a retained menstrual or wound source can cause another staphylococcal toxic-shock episode.

09Monitoring and follow-upTreatment response, safety checks and longer-term review.

Use continuous haemodynamic and oxygen monitoring and record lactate, perfusion, urine output and vasopressor dose during shock.
Repeat complete skin, wound, genital and device examination because a concealed toxin source may become apparent after resuscitation.
Trend platelets, coagulation, renal, liver, CK, acid-base and electrolytes to guide multiorgan support.
Review blood and source cultures daily and document narrowing, clindamycin stop criteria and antimicrobial duration.
Monitor the operative site and arrange rapid re-exploration for continuing pain, necrosis, fever or vasopressor requirement.
During recovery monitor desquamation, secondary infection, neuropathy, renal function, mobility, nutrition and psychological sequelae.

10Special situationsVariants, exceptions and circumstances that change the usual approach.

Desquamation is retrospective

Palm and sole peeling often appears during recovery and may confirm the syndrome, but waiting for it before treatment is dangerous.

Staphylococcal blood cultures may be negative

A local toxin-producing focus can cause profound systemic illness without organisms circulating detectably in blood.

Streptococcal pain points to source

Severe focal pain may identify occult necrotising fascia or myositis before dramatic skin change develops.

Foreign material sustains toxin

A tampon or nasal pack can remain a small-looking but biologically active source until it is physically removed.

Clindamycin is mechanistic therapy

Protein-synthesis inhibition reduces toxin production and retains activity in high-inoculum stationary-phase bacteria, but it still needs a bactericidal partner.

IVIG is an escalation decision

Potential toxin neutralisation does not compensate for delayed debridement, inactive antibiotics or inadequate shock support.

11Common pitfallsFrequent interpretation and management errors.

01
Do not wait for desquamation or complete surveillance criteria before treating a compatible shock syndrome.
02
Do not overlook tampons, nasal packing, postpartum genital infection or a concealed operative wound.
03
Do not use clindamycin alone as broad empirical or definitive bactericidal treatment.
04
Do not assume negative blood cultures exclude staphylococcal toxic shock.
05
Do not let imaging or a laboratory score delay debridement of suspected necrotising infection.
06
Do not reach for intravenous immunoglobulin before verifying source control, active therapy and full critical-care support.